# Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-of-dabrafenib-and-trametinib-in-combination-as-adjuvant/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Margaret E. Gerbasi,Daniel Stellato,Sameer R. Ghate,Briana Ndife,Aaron Moynahan,Dinesh Kumar Mishra,P Gunda,Roy Koruth,Thomas E. Delea |
| Citations | 14 |
| DOI | 10.1080/13696998.2019.1635487 |
| Fields | Biochemistry, Genetics and Molecular Biology,Economics, Econometrics and Finance,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1635487?needAccess=true |
| OpenAlex ID | https://openalex.org/W2950647279 |
| PMID | 31223037 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Briana Ndife](https://scholariq.org/researchers/briana-ndife/)

## Paper journal

- [Journal of Medical Economics](https://scholariq.org/journals/journal-of-medical-economics/)

## Paper primary topic

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Paper topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.